§355–2. Actions for delays of generic drugs and biosimilar biological products — Inbound Citations

Citations to §355–2(a)

• 21 U.S.C. § 355–1(l)

  Go to provision →
  (l) The provision of samples of a covered product to an eligible product developer (as those terms are defined in section 355–2(a) of this title) shall not be considered a violation of the requirements of any risk evaluation and mitigation strategy that may be in place under this section for such drug.